ConductScience.org, home

Paper29579331

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Gold KA and 5 others. Cancer, 2018. Cited by 94 papers, by iCite.

Cite this record

ConductScience Library. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Papers, record 29579331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29579331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
PubMed
Journal
Cancer
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
3.97
iCite
Revised in PubMed
2023-11-12
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gold KAKathryn Ahttps://orcid.org/0000-0001-5165-4424
2Kies MSMerrill S
3William WN JrWilliam N
4Johnson FMFaye M
5Lee JJJ Jack
6Glisson BSBonnie S

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Squamous CellMajor topic
Erlotinib HydrochlorideMajor topic
Neoplasm Recurrence, LocalMajor topic
Protein Kinase InhibitorsMajor topic
Skin NeoplasmsMajor topic
Aged
Aged, 80 and over
Disease Progression
ErbB Receptors
Feasibility Studies
Female
Humans
Male
Middle Aged
Response Evaluation Criteria in Solid Tumors

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER
R01 CA190628NCI NIH HHSUnited StatesR01CA190628PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01198028Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell CarcinomaDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116014882Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med2005https://conductscience.org/library/papers/16014882PubMed
225765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
327061826Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.Br J Dermatol2017https://conductscience.org/library/papers/27061826PubMed
44038911Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.Cancer1985https://conductscience.org/library/papers/4038911PubMed
51698529Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.Cancer1990https://conductscience.org/library/papers/1698529PubMed
615865067Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin.Anticancer Res2005https://conductscience.org/library/papers/15865067PubMed
727059424Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.Br J Dermatol2016https://conductscience.org/library/papers/27059424PubMed
811274625Cutaneous squamous-cell carcinoma.N Engl J Med2001https://conductscience.org/library/papers/11274625PubMed
916257339
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet2005https://conductscience.org/library/papers/16257339PubMed
1010025376Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin.Am J Clin Oncol1999https://conductscience.org/library/papers/10025376PubMed
1125303977Mutational landscape of aggressive cutaneous squamous cell carcinoma.Clin Cancer Res2014https://conductscience.org/library/papers/25303977PubMed
1218784157Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?Oncologist2008https://conductscience.org/library/papers/18784157PubMed
1321810686Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.J Clin Oncol2011https://conductscience.org/library/papers/21810686PubMed
1428964539Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.J Am Acad Dermatol2017https://conductscience.org/library/papers/28964539PubMed
1519097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1625409260Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med2014https://conductscience.org/library/papers/25409260PubMed
1715681519Mortality risk from squamous cell skin cancer.J Clin Oncol2005https://conductscience.org/library/papers/15681519PubMed
1822261807A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.Clin Cancer Res2012https://conductscience.org/library/papers/22261807PubMed
1923375456Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.J Am Acad Dermatol2013https://conductscience.org/library/papers/23375456PubMed
2020231499Incidence estimate of nonmelanoma skin cancer in the United States, 2006.Arch Dermatol2010https://conductscience.org/library/papers/20231499PubMed

Download CSV of references

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
41458609Mechanism of action of Butein in cutaneous squamous cell carcinoma through regulation of the TWEAK-FN14 signaling pathway.Front Oncol2025https://conductscience.org/library/papers/41458609PubMed
41228268Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients.Cancers (Basel)2025https://conductscience.org/library/papers/41228268PubMed
40632444The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.Curr Treat Options Oncol2025https://conductscience.org/library/papers/40632444PubMed
40405694Cetuximab plus 5-fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study.J Dtsch Dermatol Ges2025https://conductscience.org/library/papers/40405694PubMed
40110500The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives.Drug Des Devel Ther2025https://conductscience.org/library/papers/40110500PubMed
39582977KS-cSCC-1 and KS-cSCC-2: two novel cutaneous squamous cell carcinoma cell lines established from Japanese patients.Front Med (Lausanne)2024https://conductscience.org/library/papers/39582977PubMed
39199674The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review.Cancers (Basel)2024https://conductscience.org/library/papers/39199674PubMed
39050978Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices.Cancer Manag Res2024https://conductscience.org/library/papers/39050978PubMed
39000164Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.Int J Mol Sci2024https://conductscience.org/library/papers/39000164PubMed
38954315Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.Curr Oncol Rep2024https://conductscience.org/library/papers/38954315PubMed
38929802The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.J Pers Med2024https://conductscience.org/library/papers/38929802PubMed
38791879Cutaneous Squamous Cell Carcinoma: An Updated Review.Cancers (Basel)2024https://conductscience.org/library/papers/38791879PubMed
38655092Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.EXCLI J2024https://conductscience.org/library/papers/38655092PubMed
38471711High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.J Immunother Cancer2024https://conductscience.org/library/papers/38471711PubMed
37848259Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.J Immunother Cancer2023https://conductscience.org/library/papers/37848259PubMed
37417890Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.Oncotarget2023https://conductscience.org/library/papers/37417890PubMed
37235052Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience2023https://conductscience.org/library/papers/37235052PubMed
35954316Advances in Cutaneous Squamous Cell Carcinoma Management.Cancers (Basel)2022https://conductscience.org/library/papers/35954316PubMed
35620707
Sequencing of Cutaneous Squamous Cell Carcinoma Primary Tumors and Patient-Matched Metastases Reveals ALK as a Potential Driver in Metastases and Low Mutational Concordance in Immunocompromised Patients.
JID Innov2022https://conductscience.org/library/papers/35620707PubMed
35454779Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy.Cancers (Basel)2022https://conductscience.org/library/papers/35454779PubMed

See all 54 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ERLOTINIBCHEMBL553Derived from the trial1https://conductscience.org/library/drugs/CHEMBL553

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29579331

GET https://conductscience.org/api/papers/v1/29579331/cited_by?page=2